Blood products of human origin are essential treatment options for several diseases, for example, hemophilia. We studied the alignment of national essential medicines lists (NEMLs) of low- and middle-income countries (LMICs) with the World Health Organization (WHO) Model List for the selection of blood products of human origin. The most recent versions of NEMLs from all LMICs were studied for the inclusion of blood products of human origin (blood and blood components, plasma products, and immunoglobulins). Data obtained from 105 NEMLs were compared to the 2017 WHO Model List. The median number of blood products of human origin on the NEMLs was 4 (range: 0-10). Immunoglobulins were most frequently included (73%). Blood and blood components were the least selected products (15%). The uptake of plasma products was around 50%. Nine countries did not have any blood products of human origin on their NEMLs. Some NEMLs included blood products not listed on the WHO Model List (albumin, hepatitis A immunoglobulin, and cryoprecipitate). We observed variation in selection according to WHO region, income level, and year of NEML update. Alignment of NEMLs with the WHO Model List varied greatly for different groups of blood products, ranging from good uptake for immunoglobulins, reasonable uptake for plasma products, to poor uptake for blood and blood components. This heterogeneity in selection and inclusion of blood products of human origin on NEMLs may be partly explained as being due to specific country characteristics, but some of it may not be explained. Policy makers need to rely on evidence in making decisions about which blood products to select, include, and remove on their NEMLs.

人类血制品是几种疾病（例如血友病）的基本治疗选择。我们研究了低收入和中等收入国家（LMIC）的国家基本药物清单（NEML）与世界卫生组织（WHO）模型清单的一致性，以选择人类来源的血液制品。研究了来自所有LMIC的NEML的最新版本，以包括人类来源的血液制品（血液和血液成分，血浆制品和免疫球蛋白）。将105种NEML获得的数据与2017年WHO模型清单进行了比较。NEML上人类来源血液制品的中位数为4（范围：0-10）。免疫球蛋白含量最高（73％）。血液和血液成分是选择最少的产品（15％）。血浆产品的吸收率约为50％。九个国家的NEML上没有任何人类血制品。一些NEML包括未列入WHO模型清单的血液产品（白蛋白，甲型肝炎免疫球蛋白和冷沉淀）。我们观察到根据WHO区域，收入水平和NEML更新年份的选择差异。NEML与WHO模型清单的匹配因不同类别的血液产品而异，从免疫球蛋白的良好摄取，血浆产品的合理摄取到血液和血液成分的摄取不等。NEMLs上人类来源的血液制品的选择和包容性的这种异质性可以部分地解释为是由于特定的国家/地区特征造成的，但其中的某些特征可能无法解释。政策制定者需要依靠证据来决定选择哪种血液产品，包括